Roivant Sciences (NasdaqGM:ROIV) - Share price, News & Analysis

ROIV fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

ROIV Stock Overview

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.

Rewards

Revenue is forecast to grow 58.12% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Significant insider selling over the past 3 months

Roivant Sciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Roivant Sciences
Historical stock prices
Current Share Price	US$4.79
52 Week High	US$16.76
52 Week Low	US$2.52
Beta	0
1 Month Change	21.27%
3 Month Change	-3.82%
1 Year Change	-51.57%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-53.94%

Shareholder Returns

	ROIV	US Pharmaceuticals	US Market
7D	9.4%	9.1%	6.6%
1Y	-51.6%	12.5%	-18.5%

Return vs Industry: ROIV underperformed the US Pharmaceuticals industry which returned 10.6% over the past year.

Return vs Market: ROIV underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is ROIV's price volatile compared to industry and market?
ROIV volatility
ROIV Average Weekly Movement	13.6%
Pharmaceuticals Industry Average Movement	11.5%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ROIV is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ROIV's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	620	Matt Gline	https://roivant.com

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Fundamentals Summary

How do Roivant Sciences's earnings and revenue compare to its market cap?
ROIV fundamental statistics
Market Cap	US$3.32b
Earnings (TTM)	-US$1.08b
Revenue (TTM)	US$61.21m

54.2x

P/S Ratio

-3.1x

P/E Ratio

Is ROIV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ROIV income statement (TTM)
Revenue	US$61.21m
Cost of Revenue	US$8.99m
Gross Profit	US$52.22m
Other Expenses	US$1.14b
Earnings	-US$1.08b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Jun 28, 2022

Earnings per share (EPS)	-1.57
Gross Margin	85.32%
Net Profit Margin	-1,772.23%
Debt/Equity Ratio	9.0%

How did ROIV perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is ROIV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ROIV?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ROIV. This is calculated by dividing ROIV's market cap by their current preferred multiple.
What is ROIV's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$3.32b

ROIV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	29.1x
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ROIV's PB Ratio compare to its peers?

ROIV PB Ratio vs Peers

The above table shows the PB ratio for ROIV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	3.8x

Price-To-Book vs Peers: ROIV is good value based on its Price-To-Book Ratio (1.8x) compared to the peer average (3.8x).

Price to Earnings Ratio vs Industry

How does ROIV's PE Ratio compare vs other companies in the U.S. Pharmaceuticals Industry?

Price-To-Book vs Industry: ROIV is good value based on its Price-To-Book Ratio (1.8x) compared to the US Pharmaceuticals industry average (1.8x)

Price to Book Ratio vs Fair Ratio

What is ROIV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ROIV PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.8x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ROIV's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ROIV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ROIV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ROIV's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ROIV's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Roivant Sciences forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

17.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ROIV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ROIV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ROIV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ROIV's revenue (58.1% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: ROIV's revenue (58.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ROIV is forecast to be unprofitable in 3 years.

Discover growth companies

Past Performance

How has Roivant Sciences performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-201.6%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: ROIV is currently unprofitable.

Growing Profit Margin: ROIV is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ROIV's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ROIV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ROIV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.7%).

Return on Equity

High ROE: ROIV has a negative Return on Equity (-52.69%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Roivant Sciences's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ROIV's short term assets ($2.3B) exceed its short term liabilities ($160.7M).

Long Term Liabilities: ROIV's short term assets ($2.3B) exceed its long term liabilities ($368.9M).

Debt to Equity History and Analysis

Debt Level: ROIV has more cash than its total debt.

Reducing Debt: Insufficient data to determine if ROIV's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ROIV has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ROIV has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 22.4% each year.

Discover healthy companies

Dividend

What is Roivant Sciences's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ROIV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ROIV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ROIV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ROIV's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ROIV has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure

CEO

Matt Gline (37 yo)

1.42yrs

Tenure

US$8,310,550

Compensation

Mr. Matthew Gline, also known as Matt, is Chief Executive Officer of Roivant Sciences Ltd. since January 26, 2021 and its Director since September 30, 2021. He has been Chief Executive Officer of Roivant S...

CEO Compensation Analysis

Compensation vs Market: Matt's total compensation ($USD8.31M) is about average for companies of similar size in the US market ($USD6.92M).

Compensation vs Earnings: Insufficient data to compare Matt's compensation with company performance.

Leadership Team

Experienced Management: ROIV's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: ROIV's board of directors are considered experienced (3.4 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: ROIV insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/24 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/03/31